Patient and treatment characteristics
Characteristic . | Value . |
|---|---|
| No. of patients | 63 |
| Median age, y (range) | 53 (19-71) |
| Diagnosis, no. (%) | |
| AML | 8 (13) |
| ALL | 4 (6) |
| MDS | 16 (25) |
| CML | 4 (6) |
| AMM | 10 (16) |
| LPD | 16 (25) |
| Other | 5 (8) |
| Advanced disease, no. (%)* | 24 (38) |
| Donor, no. (%) | |
| Sibling donor | 38 (60) |
| Unrelated donor | 25 (40) |
| Median donor age, y (range) | |
| Sibling donor | 50 (24-71) |
| Unrelated donor | 38 (20-52) |
| Donor-recipient genders mismatch, no. (%) | |
| F to M | 18 (29) |
| M to F | 13 (21) |
| CMV serology, no. (%) | |
| D and/or R (+) | 42 (67) |
| D and R (-) | 21 (33) |
| ABO incompatibility, no. (%) | |
| Major ± minor | 30 (48) |
| Preparative regimen, no. (%) | |
| TBI 200 cGy | 8 (13) |
| TBI 200 cGy + fludarabine | 55 (87) |
| Median follow-up for surviving patients, mo (range) | 13 (5-45) |
Characteristic . | Value . |
|---|---|
| No. of patients | 63 |
| Median age, y (range) | 53 (19-71) |
| Diagnosis, no. (%) | |
| AML | 8 (13) |
| ALL | 4 (6) |
| MDS | 16 (25) |
| CML | 4 (6) |
| AMM | 10 (16) |
| LPD | 16 (25) |
| Other | 5 (8) |
| Advanced disease, no. (%)* | 24 (38) |
| Donor, no. (%) | |
| Sibling donor | 38 (60) |
| Unrelated donor | 25 (40) |
| Median donor age, y (range) | |
| Sibling donor | 50 (24-71) |
| Unrelated donor | 38 (20-52) |
| Donor-recipient genders mismatch, no. (%) | |
| F to M | 18 (29) |
| M to F | 13 (21) |
| CMV serology, no. (%) | |
| D and/or R (+) | 42 (67) |
| D and R (-) | 21 (33) |
| ABO incompatibility, no. (%) | |
| Major ± minor | 30 (48) |
| Preparative regimen, no. (%) | |
| TBI 200 cGy | 8 (13) |
| TBI 200 cGy + fludarabine | 55 (87) |
| Median follow-up for surviving patients, mo (range) | 13 (5-45) |
ALL indicates acute lymphocytic leukemia; AML, acute myeloid leukemia; AMM, agnogenic myeloid metaplasia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; CSP, cyclosporine; D, donor; F, female; GVHD, graft-versus-host disease; LPD, lymphoproliferative disorder; M, male; MDS, myelodysplastic syndrome; MMF, mycophenolate; R, recipient; and TBI, total body irradiation.
Advanced disease: acute leukemia beyond first remission, refractory anemia, or chronic myelomonocytic leukemia with excess blasts, chronic myeloid leukemia beyond first chronic phase, lymphoproliferative disorder beyond second remission or refractory, and agnogenic myeloid metaplasia with excess blasts